Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Autoimmune Disorders

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 133 articles:
HTML format
Text format



Single Articles


    November 2017
  1. RUPRECHT K, Wildemann B, Jarius S
    Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.
    J Neurol. 2017 Nov 2. doi: 10.1007/s00415-017-8656.
    PubMed     Text format     Abstract available


    October 2017
  2. COMI G, Patti F, Rocca MA, Mattioli FC, et al
    Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8642.
    PubMed     Text format     Abstract available


  3. PARDO G, Jones DE
    Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8633.
    PubMed     Text format     Abstract available


  4. ABBOUD H, Rossman I, Mealy MA, Hill E, et al
    Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.
    J Neurol. 2017 Oct 3. doi: 10.1007/s00415-017-8627.
    PubMed     Text format     Abstract available


    September 2017
  5. WANG L, Zhang S, Xi J, Li W, et al
    Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2017 Sep 18. doi: 10.1007/s00415-017-8616.
    PubMed     Text format     Abstract available


  6. LOREFICE L, Coghe G, Fenu G, Porta M, et al
    'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.
    J Neurol. 2017 Sep 11. doi: 10.1007/s00415-017-8612.
    PubMed     Text format     Abstract available


  7. PARDO G, Jones DE
    The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Sep 6. doi: 10.1007/s00415-017-8594.
    PubMed     Text format     Abstract available


    August 2017
  8. LATTANZI S, Danni M, Taffi R, Cerqua R, et al
    Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    J Neurol. 2017 Aug 22. doi: 10.1007/s00415-017-8595.
    PubMed     Text format     Abstract available


  9. HRASTELJ J, Robertson N
    Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8584.
    PubMed     Text format    


  10. FINKE C, Bartels F, Lutt A, Pruss H, et al
    High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8582.
    PubMed     Text format     Abstract available


    July 2017
  11. EICHINGER P, Wiestler H, Zhang H, Biberacher V, et al
    A novel imaging technique for better detecting new lesions in multiple sclerosis.
    J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8576.
    PubMed     Text format     Abstract available


  12. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Erratum to: Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jul 10. doi: 10.1007/s00415-017-8556.
    PubMed     Text format    


    June 2017
  13. CASEY JP, Hirouchi T, Hisatsune C, Lynch B, et al
    A novel gain-of-function mutation in the ITPR1 suppressor domain causes spinocerebellar ataxia with altered Ca2+ signal patterns.
    J Neurol. 2017 Jun 15. doi: 10.1007/s00415-017-8545.
    PubMed     Text format     Abstract available


  14. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jun 12. doi: 10.1007/s00415-017-8541.
    PubMed     Text format     Abstract available


  15. HAGSTROM IT, Schneider R, Bellenberg B, Salmen A, et al
    Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    J Neurol. 2017 Jun 9. doi: 10.1007/s00415-017-8537.
    PubMed     Text format     Abstract available


    May 2017
  16. BRITZE J, Pihl-Jensen G, Frederiksen JL
    Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.
    J Neurol. 2017 May 31. doi: 10.1007/s00415-017-8531.
    PubMed     Text format     Abstract available


  17. DIBLEY L, Coggrave M, McClurg D, Woodward S, et al
    "It's just horrible": a qualitative study of patients' and carers' experiences of bowel dysfunction in multiple sclerosis.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8527.
    PubMed     Text format     Abstract available


  18. RATH J, Mauritz M, Zulehner G, Hilger E, et al
    Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8518.
    PubMed     Text format     Abstract available


  19. RIVIERE E, Cohen Aubart F, Maisonobe T, Maurier F, et al
    Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study.
    J Neurol. 2017 May 23. doi: 10.1007/s00415-017-8519.
    PubMed     Text format     Abstract available


  20. FOULON S, Maura G, Dalichampt M, Alla F, et al
    Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8513.
    PubMed     Text format     Abstract available


  21. CORDTS I, Bodart N, Hartmann K, Karagiorgou K, et al
    Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8514.
    PubMed     Text format     Abstract available


  22. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Text format     Abstract available


    April 2017
  23. HARDING K, Tilling K, MacIver C, Willis M, et al
    Seasonal variation in multiple sclerosis relapse.
    J Neurol. 2017 Apr 19. doi: 10.1007/s00415-017-8485.
    PubMed     Text format     Abstract available


  24. SARTORI A, Abdoli M, Freedman MS
    Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    J Neurol. 2017 Apr 17. doi: 10.1007/s00415-017-8487.
    PubMed     Text format     Abstract available


  25. HAINLINE C, Rizzo JR, Hudson TE, Dai W, et al
    Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.
    J Neurol. 2017 Apr 7. doi: 10.1007/s00415-017-8484.
    PubMed     Text format     Abstract available


  26. CHOI HA, Lee MJ, Chung CS
    Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.
    J Neurol. 2017;264:724-732.
    PubMed     Text format     Abstract available


  27. BARTOLINI L, Muscal E
    Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.
    J Neurol. 2017;264:647-653.
    PubMed     Text format     Abstract available


    March 2017
  28. HONG Y, Skeie GO, Zisimopoulou P, Karagiorgou K, et al
    Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
    J Neurol. 2017 Mar 31. doi: 10.1007/s00415-017-8478.
    PubMed     Text format     Abstract available


  29. PREZIOSA P, Martinelli V, Ferre L, Guaschino C, et al
    Moyamoya disease mimicking the first attack of multiple sclerosis.
    J Neurol. 2017 Mar 17. doi: 10.1007/s00415-017-8458.
    PubMed     Text format    


  30. MCLAUCHLAN D, Robertson NP
    B cell treatments for multiple sclerosis.
    J Neurol. 2017 Mar 4. doi: 10.1007/s00415-017-8442.
    PubMed     Text format    


  31. ROODBOL J, de Wit MY, van den Berg B, Kahlmann V, et al
    Diagnosis of Guillain-Barre syndrome in children and validation of the Brighton criteria.
    J Neurol. 2017 Mar 1. doi: 10.1007/s00415-017-8429.
    PubMed     Text format     Abstract available


  32. KHAN F, Amatya B, Galea MP, Gonzenbach R, et al
    Neurorehabilitation: applied neuroplasticity.
    J Neurol. 2017;264:603-615.
    PubMed     Text format     Abstract available


    February 2017
  33. DULAU C, Deloire M, Diaz H, Saubusse A, et al
    Social cognition according to cognitive impairment in different clinical phenotypes of multiple sclerosis.
    J Neurol. 2017 Feb 20. doi: 10.1007/s00415-017-8417.
    PubMed     Text format     Abstract available


  34. NIJ BIJVANK JA, Balk LJ, Tan HS, Uitdehaag BM, et al
    A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer.
    J Neurol. 2017 Feb 13. doi: 10.1007/s00415-017-8412.
    PubMed     Text format    


  35. MALONEY E, Molloy A, Al Hussona M, O'Donnell L, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    J Neurol. 2017;264:401-403.
    PubMed     Text format    


    January 2017
  36. TAYLOR CJ, Hirsch NP, Kullmann DM, Howard RS, et al
    Changes in the severity and subtype of Guillain-Barre syndrome admitted to a specialist Neuromedical ICU over a 25 year period.
    J Neurol. 2017 Jan 16. doi: 10.1007/s00415-016-8380.
    PubMed     Text format     Abstract available


  37. BIANCHI A, Bartolini E, Melani F, Guerrini R, et al
    Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies.
    J Neurol. 2017;264:179-181.
    PubMed     Text format    


    December 2016
  38. HYNCICOVA E, Vyhnalek M, Kalina A, Martinkovic L, et al
    Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis.
    J Neurol. 2016 Dec 27. doi: 10.1007/s00415-016-8368.
    PubMed     Text format     Abstract available


  39. JARIUS S, Eichhorn P, Franciotta D, Petereit HF, et al
    The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.
    J Neurol. 2016 Dec 22. doi: 10.1007/s00415-016-8360.
    PubMed     Text format     Abstract available


  40. JONES LA, Robertson NP
    An update on treatments in myasthenia gravis.
    J Neurol. 2016 Dec 20. doi: 10.1007/s00415-016-8359.
    PubMed     Text format    


  41. BRECKWOLDT MO, Gradl J, Hahnel S, Hielscher T, et al
    Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  42. GIORLI E, Franciotta D, Beronio A, Amodeo C, et al
    Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD.
    J Neurol. 2016;263:2549-2551.
    PubMed     Text format    


  43. HUSS AM, Halbgebauer S, Ockl P, Trebst C, et al
    Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
    J Neurol. 2016;263:2499-2504.
    PubMed     Text format     Abstract available


  44. HUANG Q, Wu Y, Qin R, Wei X, et al
    Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
    J Neurol. 2016;263:2446-2455.
    PubMed     Text format     Abstract available


    November 2016
  45. BLOCK VJ, Lizee A, Crabtree-Hartman E, Bevan CJ, et al
    Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  46. BLASCO MR, Ramos A, Malo CG, Garcia-Merino A, et al
    Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  47. SCHWARTZBACH CJ, Grove RA, Brown R, Tompson D, et al
    Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  48. PROSPERINI L, Sacca F, Cordioli C, Cortese A, et al
    Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  49. KOSMIDOU M, Katsanos AH, Katsanos KH, Kyritsis AP, et al
    Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  50. HAVLA J, Kumpfel T, Schinner R, Spadaro M, et al
    Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  51. DRESSLER D, Bhidayasiri R, Bohlega S, Chahidi A, et al
    Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  52. PAKPOOR J, Goldacre R, Goldacre MJ
    Low testosterone and myasthenia gravis in males: a national record-linkage study.
    J Neurol. 2016.
    PubMed     Text format    


  53. VAN GEEST Q, Westerik B, van der Werf YD, Geurts JJ, et al
    The role of sleep on cognition and functional connectivity in patients with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  54. THORMANN A, Magyari M, Koch-Henriksen N, Laursen B, et al
    Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  55. PIETRZAK K, Grzybowski A, Kaczmarczyk J
    Georges Guillain (1876-1961).
    J Neurol. 2016;263:2148-9.
    PubMed     Text format    


  56. ABSINTA M, Reich DS, Filippi M
    Spring cleaning: time to rethink imaging research lines in MS?
    J Neurol. 2016;263:1893-902.
    PubMed     Text format     Abstract available


    September 2016
  57. OWEN PICKRELL W, Robertson NP
    Stem cell treatment for multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  58. HEINE J, Ly LT, Lieker I, Slowinski T, et al
    Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  59. MAILAND MT, Frederiksen JL
    Vaccines and multiple sclerosis: a systematic review.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  60. MAILLART E, Papeix C, Mellerio C, Bertrand A, et al
    Extensive and severe CNS demyelination associated with golimumab therapy.
    J Neurol. 2016;263:1869-71.
    PubMed     Text format    


  61. LOZERON P, Ribrag V, Adams D, Brisset M, et al
    Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?
    J Neurol. 2016;263:1761-70.
    PubMed     Text format     Abstract available


  62. ANNOVAZZI P, Capobianco M, Moiola L, Patti F, et al
    Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    J Neurol. 2016;263:1727-35.
    PubMed     Text format     Abstract available


    August 2016
  63. EL AYOUBI NK, Ghassan S, Said M, Allam J, et al
    Retinal measures correlate with cognitive and physical disability in early multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  64. MOBERG JY, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  65. SCHIRMER L, Worthington V, Solloch U, Loleit V, et al
    Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barre syndrome.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  66. ZURAWSKI J, Flinn A, Sklover L, Sloane JA, et al
    Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    J Neurol. 2016;263:1511-7.
    PubMed     Text format     Abstract available


    July 2016
  67. ZIEMSSEN T, Phillips G, Shah R, Mathias A, et al
    Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ).
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  68. ZHOU H, Zhao S, Yin D, Chen X, et al
    Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
    J Neurol. 2016;263:1382-9.
    PubMed     Text format     Abstract available


  69. JEONG IH, Kim HJ, Kim NH, Jeong KS, et al
    Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
    J Neurol. 2016;263:1343-8.
    PubMed     Text format     Abstract available


  70. BALK LJ, Cruz-Herranz A, Albrecht P, Arnow S, et al
    Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
    J Neurol. 2016;263:1323-31.
    PubMed     Text format     Abstract available


  71. HAVRDOVA E, Belova A, Goloborodko A, Tisserant A, et al
    Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
    J Neurol. 2016;263:1287-95.
    PubMed     Text format     Abstract available


    June 2016
  72. BERCIANO J, Sedano MJ, Pelayo-Negro AL, Garcia A, et al
    Proximal nerve lesions in early Guillain-Barre syndrome: implications for pathogenesis and disease classification.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  73. PRIETO-MORIN C, Ayrignac X, Ellie E, Tournier-Lasserve E, et al
    CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  74. D'AMICO E, Leone C, Zanghi A, Fermo SL, et al
    Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  75. KALRON A, Givon U
    Gait characteristics according to pyramidal, sensory and cerebellar EDSS subcategories in people with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  76. NEWSOME SD, Kieseier BC, Arnold DL, Shang S, et al
    Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  77. HOSOKAWA T, Nakajima H, Unoda K, Yamane K, et al
    Serial electrophysiological findings in Guillain-Barre syndrome not fulfilling AIDP or AMAN criteria.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  78. JONGEN PJ, Stavrakaki I, Voet B, Hoogervorst E, et al
    Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  79. MICLEA A, Leussink VI, Hartung HP, Gold R, et al
    Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  80. IAFFALDANO P, Viterbo RG, Trojano M
    Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  81. BRIER MR, Day GS, Snyder AZ, Tanenbaum AB, et al
    N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI.
    J Neurol. 2016;263:1083-91.
    PubMed     Text format     Abstract available


  82. GRIMM A, Vittore D, Schubert V, Rasenack M, et al
    Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
    J Neurol. 2016;263:1074-82.
    PubMed     Text format     Abstract available


    May 2016
  83. BEER A, Biberacher V, Schmidt P, Righart R, et al
    Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  84. SCHIPPLING S, O'Connor P, Knappertz V, Pohl C, et al
    Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  85. AMANN M, Pezold S, Naegelin Y, Fundana K, et al
    Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  86. DAVION JB, Cambron M, Duhin E, Chouraki A, et al
    Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  87. SEPULVEDA M, Armangue T, Martinez-Hernandez E, Arrambide G, et al
    Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  88. VINJAM MR, Shanmugarajah P, Ford HL
    Ophthalmoplegia heralding the onset of anti-amphiphysin related paraneoplastic stiff person syndrome.
    J Neurol. 2016;263:1017-8.
    PubMed     Text format    


    April 2016
  89. MCCARTHY C, Thorpe J
    Some recent advances in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  90. GAETANI L, Mignarri A, Di Gregorio M, Sarchielli P, et al
    Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
    J Neurol. 2016.
    PubMed     Text format    


  91. DE KOUCHKOVSKY I, Fieremans E, Fleysher L, Herbert J, et al
    Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  92. GROTHE M, Lotze M, Langner S, Dressel A, et al
    The role of global and regional gray matter volume decrease in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  93. SANDROFF BM, Schwartz CE, DeLuca J
    Measurement and maintenance of reserve in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  94. FAISSNER S, Nikolayczik J, Chan A, Hellwig K, et al
    Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  95. TALLANTYRE EC, Robertson NP
    Continuous evolution of magnetic resonance imaging in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  96. MATRICARDI S, Patrini M, Freri E, Ragona F, et al
    Cognitive and neuropsychological evolution in children with anti-NMDAR encephalitis.
    J Neurol. 2016;263:765-71.
    PubMed     Text format     Abstract available


    March 2016
  97. HALBGEBAUER S, Huss A, Buttmann M, Steinacker P, et al
    Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  98. RAGGI A, Leonardi M, Schiavolin S, Antozzi C, et al
    Validation of the MG-DIS: a disability assessment for myasthenia gravis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  99. HUSSAIN R, O'Leary S, Pacheco FM, Zacharias TE, et al
    Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
    J Neurol. 2016;263:606-10.
    PubMed     Text format     Abstract available


  100. FILIPPI M, Barker RA, Strupp M
    The neurology community mourns the passing of Dr. John F. Kurtzke.
    J Neurol. 2016;263:421.
    PubMed     Text format    


  101. AYZENBERG I, Schollhammer J, Hoepner R, Hellwig K, et al
    Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
    J Neurol. 2016;263:575-82.
    PubMed     Text format     Abstract available


    February 2016
  102. BUTTERWORTH SE, Ingram G, Robertson NP
    Advances in biomarker research in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  103. BARNETT MH, McLeod JG, Hammond SR, Kurtzke JF, et al
    Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  104. ZIEMSSEN T, Calabrese P, Penner IK, Apfel R, et al
    QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naive patients, and previously treated patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  105. MELZER N, Ruck T, Fuhr P, Gold R, et al
    Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  106. LADWIG A, Dunkl V, Richter N, Schroeter M, et al
    Two cases of multiple sclerosis manifesting after in vitro fertilization procedures.
    J Neurol. 2016.
    PubMed     Text format    


  107. BARGAGLI AM, Colais P, Agabiti N, Mayer F, et al
    Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  108. MATAS E, Bau L, Martinez-Iniesta M, Romero-Pinel L, et al
    Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  109. ORTIZ-PEREZ S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, et al
    Visual field impairment captures disease burden in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  110. PICCOLO L, Woodhall M, Tackley G, Jurynczyk M, et al
    Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    J Neurol. 2016;263:370-9.
    PubMed     Text format     Abstract available


  111. JEFFERY DR, Di Cantogno EV, Ritter S, Meier DP, et al
    The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
    J Neurol. 2016;263:299-305.
    PubMed     Text format     Abstract available


    January 2016
  112. DOTY RL, Tourbier IA, Pham DL, Cuzzocreo JL, et al
    Taste dysfunction in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  113. JORDAN B, Kellner J, Jordan K, Bahre M, et al
    Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  114. KIM G, Tauhid S, Dupuy SL, Tummala S, et al
    An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  115. BOVE R, McHenry A, Hellwig K, Houtchens M, et al
    Multiple sclerosis in men: management considerations.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  116. BAYSAL-KIRAC L, Tuzun E, Erdag E, Ulusoy C, et al
    Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  117. ABKUR TM, Foran E, Kearney H, Harkin G, et al
    Neuromyelitis optica presenting as intractable vomiting and hyperCKaemia.
    J Neurol. 2016;263:171-3.
    PubMed     Text format    


  118. JURYNCZYK M, Weinshenker B, Akman-Demir G, Asgari N, et al
    Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.
    J Neurol. 2016;263:140-9.
    PubMed     Text format     Abstract available


  119. AZZOPARDI L, Cox AL, McCarthy CL, Jones JL, et al
    Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
    J Neurol. 2016;263:25-9.
    PubMed     Text format     Abstract available


    December 2015
  120. ZIEMSSEN T, Derfuss T, de Stefano N, Giovannoni G, et al
    Optimizing treatment success in multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  121. BINKS S, Vincent A, Palace J
    Myasthenia gravis: a clinical-immunological update.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  122. JORDAN B, Schilling S, Zierz S
    Switch to double positive late onset MuSK myasthenia gravis following thymomectomy in paraneoplastic AChR antibody positive myasthenia gravis.
    J Neurol. 2015.
    PubMed     Text format    


  123. KAPPOS L, Radue EW, Chin P, Ritter S, et al
    Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  124. BRAUNE S, Lang M, Bergmann A
    Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  125. SALZER J, Lycke J, Wickstrom R, Naver H, et al
    Rituximab in paediatric onset multiple sclerosis: a case series.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  126. KRUMBHOLZ M, Hofstadt-van Oy U, Angstwurm K, Kleiter I, et al
    Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75.
    J Neurol. 2015;262:1379-84.
    PubMed     Text format     Abstract available


  127. RICE CM, Kurian KM, Renowden S, Whiteway A, et al
    Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system.
    J Neurol. 2015;262:1354-9.
    PubMed     Text format     Abstract available


    March 2015
  128. KOIKE H, Akiyama K, Saito T, Sobue G, et al
    Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial.
    J Neurol. 2015;262:752-9.
    PubMed     Text format     Abstract available


  129. KIM SH, Hyun JW, Jeong IH, Joung A, et al
    Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.
    J Neurol. 2015;262:696-700.
    PubMed     Text format     Abstract available


    February 2015
  130. KAUFMAN M, Cree BA, De Seze J, Fox RJ, et al
    Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
    J Neurol. 2015;262:326-36.
    PubMed     Text format     Abstract available


    January 2015
  131. JONKMAN LE, Soriano AL, Amor S, Barkhof F, et al
    Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study.
    J Neurol. 2015;262:1074-80.
    PubMed     Text format     Abstract available


  132. LAUDA F, Fangerau T, Javaheripour-Otto K, Pinkhardt E, et al
    Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
    J Neurol. 2015;262:1055-7.
    PubMed     Text format    


    April 2014
  133. FILIPPI M
    MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment.
    J Neurol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: